All Companies

ABBVCongressional Stock Trades

ABBVIE INC.

Pharmaceutical Preparations

Congressional stock trades in ABBVIE INC. (ABBV) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

37

Politicians Trading

13

Last Traded

Jun 2, 2026

Trading History

PoliticianNotifiedTradedTypeAmountChange
Alan ArmstrongRJul 21, 2026Mar 27, 2026Buy$15,001 - $50,000+26.06%
Julia LetlowRJan 13, 2026Apr 28, 2025Buy$1,001 - $15,000+37.24%
Lisa C. McClainRNov 21, 2025Oct 30, 2025Buy$1,001 - $15,000+15.67%
Marjorie Taylor GreeneRAug 15, 2025Aug 4, 2025Buy$1,001 - $15,000+33.86%
Lisa C. McClainRAug 13, 2025Jul 22, 2025Buy$1,001 - $15,000+41.07%
Lisa C. McClainRAug 13, 2025Jun 17, 2025Buy$1,001 - $15,000+42.31%
Robert BresnahanRJun 9, 2025May 15, 2025Buy$1,001 - $15,000+45.29%
Marjorie Taylor GreeneRMay 6, 2025May 5, 2025Buy$1,001 - $15,000+34.63%
Robert BresnahanRMar 27, 2025Feb 25, 2025Buy$1,001 - $15,000+29.30%
Marjorie Taylor GreeneRMar 19, 2025Mar 17, 2025Buy$1,001 - $15,000+23.08%
Jefferson ShreveRMar 9, 2025Feb 24, 2025Buy$50,001 - $100,000+29.34%

Price History

About ABBVIE INC.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.